Legendary regeneron chairman roy vagelos to retire at age 93

Biopharma legend P. Roy Vagelos will step down as chairman of Regeneron Pharmaceuticals after 29 years in June, at the age of

Biopharma legend P. Roy Vagelos will step down as chairman of Regeneron Pharmaceuticals after 29 years in June, at the age of At the time, Regeneron was struggling with the decision to abandon trials of a drug candidate for neurodegenerative disorder amyotrophic lateral sclerosis, forcing it to turn its attention to other pipeline projects.

Regeneron also said Christine Poon, a member of the board since , will become its lead independent director. Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and. The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Developments in the oncology space in brought hope to both industry and patients.

› pharma › end-era-regeneron-chairman-roy-vage.

The Trump administration intends to keep only essential workers at USAID, according to media reports - unless a lawsuit thwarts the plans. Regeneron chair Vagelos steps down at International Biomedical Research Alliance. Phil Taylor. Bookmark this. Exploring the future: Opportunities and challenges in cell a